EXCLUSIVE: Florida Lawmaker Introducing Psilocybin Mushroom Legalization
Forbes, 15 January, 2021
A Florida state lawmaker plans to introduce as soon as next week a bill that would legalize psilocybin-assisted therapy in the state.
Peter Thiel-backed psychedelics start-up targets schizophrenia ahead of IPO
CNBC, 15 January, 2021
Headquartered in Berlin, ATAI is aiming to make psychedelic medicines that can be used to treat mental health disorders. Recognify, meanwhile, is specifically aiming to make a medicine that can be used to treat the cognitive impairment associated with schizophrenia, or CIAS.
Talking Music, Ceremony and Psychedelic-Assisted Therapy with Tania de Jong AM
Rune Soup, 13 January, 2021
Mount Sinai Health System Launches Center for Psychedelic Research
Psychedelic Finance, 08 January, 2021
New York, Ny (January 07, 2021) The Icahn School of Medicine at Mount Sinai has launched a new center for psychedelics research. The Center for Psychedelic Psychotherapy and Trauma Research pursues a multipronged clinical and research approach to discovering novel and more efficacious therapies for post-traumatic stress disorder (PTSD), depression, anxiety, and other stress-related conditions in the veteran and civilian population.
COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care
Globe News Wire, 08 January, 2021
Why Investors Are Psyched About Psychedelic Stocks
Visual Capitalist, 07 January, 2021
Psychedelic stocks are trading like biotechnology companies these days. The prospect of promising research has pushed valuations upwards.
Big pharma is about to tune in to the potential of psychedelics
Wired, 01 January, 2021
Mainstream mental-health care will embrace alternative active substances such as psilocybin.
Why Canada Could Be Next To Allow Psychedelic Therapy (And How It’s Already Changing Lives)
Forbes, 30 December, 2020
Now, as a handful of patients and more recently doctors and therapists have been granted exemptions to use psilocybin, the nation’s federal health agency is considering making changes to existing policies that could open the door to much more than magic mushrooms.
Psychedelic drug DMT to be trialled in UK to treat depression
The Guardian, 10 December, 2020
Exclusive: UK regulators give go-ahead for drug to be trialled ahead of possible treatment alongside psychotherapy.
New Compound Related to Psychedelic Ibogaine Could Treat Addiction, Depression
UC Davis, 09 December, 2020
A non-hallucinogenic version of the psychedelic drug ibogaine, with potential for treating addiction, depression and other psychiatric disorders, has been developed by researchers at the University of California, Davis. A paper describing the work is published Dec. 9 in Nature.
Health care professionals okayed to use magic mushrooms for training in psilocybin therapy
Now Toronto, 09 December, 2020
Psychologists, psychiatrists, social workers and nurses are among 17 health care professionals granted the exemption by Health Canada this week.
Can the active ingredient in magic mushrooms help treat anxiety? Researchers want to know.
The Age, 08 December, 2020
Australia is embarking on one of the world’s largest studies into the use of psychedelic drugs for mental health, with Melbourne researchers preparing to launch a world-first clinical trial investigating whether psilocybin – the active ingredient in “magic mushrooms” – can help treat people suffering severe persistent anxiety.
Silo Pharma Plans Phase 2B Trial Testing Low-dose Psychedelics in Parkinson’s
Parkinson's News Today, 04 December, 2020
Silo Pharma is collaborating with Maastricht University on a Phase 2b clinical trial to investigate the effects of low-dose psychedelics on cognitive and emotional dysfunction in patients with Parkinson’s disease.
United Nations approves WHO recommendation to reschedule cannabis in historic vote
Marijuana Business Daily, 02 December, 2020
The United Nations Commission on Narcotic Drugs (CND) accepted a World Health Organization (WHO) recommendation to remove cannabis and cannabis resin from Schedule IV of the 1961 Single Convention on Narcotic Drugs.
Psilocybin Treatment for Mental Health Gets Legal Framework
Scientific American, 01 December, 2020
Oregon became the first state to legalize therapeutic use of the drug, as new research affirms its benefits for treating depression.
'The war on drugs failed': California lawmaker will push to decriminalise psychedelics
The Guardian, 20 November, 2020
A California lawmaker has announced he will take on the arduous battle to decriminalize psychedelics in the state, citing Oregon, which voted to decriminalize hard drugs and legalize psilocybin, and the District of Columbia, which has decriminalized psychedelics, as inspiration.
Jewish psychedelics advocate working to turn drug into legal medicine
The Jerusalem Post, 20 November, 2020
In the United States, research on these chemicals has been banned since the 1960s because, in the government’s judgment, they have no recognized medical value.
Psilocybin for Depression Study Approved and Funded by German Government
Psilocybin Alpha, 19 November, 2020
The German Government has approved a Phase 2b study on psilocybin for treatment-resistant depression, and is providing millions of Euros to this latest psychedelic research project.
Canada Is Allowing People With Depression to Do Psychedelic Mushrooms
Vice World News, 17 November, 2020
The Canadian government is allowing patients who are not terminally ill to legally consume psychedelic mushrooms.
What the U.S. Military’s $27M investment in psychedelic drugs could mean for veterans with PTSD
The Dales Report, 11 November, 2020
The U.S. Department of Defense’s Defense Advanced Research Projects Agency (DARPA) has invested nearly USD $27 million into a team of researchers led by professor of pharmacology Dr. Bryan L. Roth at the University of North Carolina School of Medicine.
Washington, DC, just decriminalized psychedelic plants. Here’s what happens next
Leafly, 04 November, 2020
Residents of the nation’s capital just took a step toward more liberal use of hallucinogens, in response to a groundswell of interest in new drugs for medical maladies.
Oregon becomes first state to legalize magic mushrooms as more states ease drug laws in ‘psychedelic renaissance’
CNBC, 04 November, 2020
Oregon on Wednesday became the first state to legalize the active ingredient in so-called magic mushrooms on an election night that saw more states ease restrictions on drugs across the country.
The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD
Plos One, 14 October, 2020
Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD
MAPS, 14 October, 2020
Healthcare cost savings of MDMA-assisted psychotherapy for PTSD estimated to be greater than $(USD)103.2 million with a return of 5,553 Quality of Life Years per 1,000 patients.
What if a Pill Can Change Your Politics or Religious Beliefs?
Eddie Jacobs, Scientific American, 11 October, 2020
The New Yorker: Turn On, Tune In, Get Well
The New Yorker, 12 October, 2020
New York is getting its first psychedelic-medicine center, with the help of a startup called MindMed, which develops hallucinogens to treat mental illness and addiction, and is funding an institute at N.Y.U. Langone Medical Center.
PsyTech Hosts Live Investor Conference & Webinar October 27, 2020 and Closes Transaction with One of the Largest Psychedelic Conferences PsyTech.biz
Global News Wire, 25 September, 2020
PsyTech Summit 2020 will be a one-day, international event bringing together decision makers, investors, clinicians, thought leaders, and advocates for the purpose of advancing psychedelics science, business, and reform. Mind Medicine Australia Executive Director, Tania de Jong AM will be presenting alongside other distinguished speakers associated with Mind Medicine Australia including Professor David Nutt, Dr Rick Doblin, Professor Matthew W. Johnson, Dr Robin Carhart-Harris, Dr Adele Lafrance and Dr Reid Robison.
The Washington Post: Who Will Benefit From Psychedelic Medicine?
Washington Post, 21 September, 2020
Who Will Benefit From Psychedelic Medicine? These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.
Mind Medicine CEO Calls Compass IPO: A 'Clear Bellwether' For Psychedelic Space
Bezinga, 19 September, 2020
On Friday, UK-based mental health care company Compass Pathways NASDAQCMPS announced it has begun trading on NASDAQ under the symbol CMPS. This is the first time a psychedelics company is listed on a major U.S. Stock Exchange.
IntelGenx inks double deals to develop oral film psychedelics for psychiatric use
Fierce Pharma, 16 September, 2020
Drug delivery specialist IntelGenx has penned two deals to develop film-based, prescription psychedelics amid a surge of interest—and investment—from the biopharma industry.
UC Berkeley launches center for psychedelic science and education
Berkeleyside, 18 September, 2020
UC Berkeley launches center for psychedelic science and education With $1.25M in seed funding, the new center will conduct research using psychedelics to investigate cognition, perception and emotion and their biological bases in the human brain.
Usona Puts New Psilocybin Synthesis Method in the Public Domain
Ann Harrison, 15 September, 2020
The nonprofit Usona Institute has developed a new technique to synthesize kilograms of pharmaceutical grade psilocybin and placed this information in the public domain where it cannot be patented.
Psychedelics For CNS Disorders: Understanding The Opportunity
Ben Comer, 09 September, 2020
Investigational uses of psilocybin and MDMA – two illicit drugs associated with recreational use and abuse in the US – will soon enter the later stages of clinical development for the treatment of CNS disorders including depression, addiction and post-traumatic stress disorder.
Breaking the stigma: Psychedelic Drugs
Cannabis Life Network, 22 August, 2020
There are a lot of negative stigma surrounding psychedelic drugs. A large portion of the population and the government condemn these substances to be dangerous, addictive, and illegal. Although, that may be true when it comes to opiates or stimulants (such as heroin or cocaine). As they are, indeed, physiologically toxic and addictive. Psychedelics, on the other hand, have been mistaken to have the same, or even worse detrimental effects to one’s health.
Silicon Valley and Wall Street Elites Pour Money Into Psychedelic Research
The Wall Street Journal, 20 August, 2020
A group of Silicon Valley and Wall Street executives has raised $30 million to speed the development of a closely watched psychedelic-drug therapy using the key ingredient of the party drug Ecstasy to treat trauma patients.
Psychedelic Science in Post-Covid Psychiatry
DocWire News, 19 August, 2020
The medium to long term consequences of COVID-19 are not yet known, though an increase in mental health problems are predicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19.
Eleusis sheds light on psychedelics that relieve asthma in rats with no mental effects
Fierce Biotech, 13 August, 2020
Psychedelic drugs like LSD have long been of interest in the medical community because of their anti-inflammatory properties. But efforts to transform them into therapeutics have been hampered by laws restricting the use of psychedelics, not to mention the stigma associated with them.
The first Canadian to legally consume psilocybin for medical purposes shares his experience
Regina Leader-Post, 21 August, 2020
Earlier this month, four Canadians received Section 56 exemption to the Controlled Drugs and Substances Act, allowing them to pursue psilocybin therapy for end-of-life distress.
Canada Will Let Terminally Ill Patients Use Psychedelic Mushrooms For End-Of-Life Care
CNN, 06 August, 2020
Four cancer patients in end-of-life care will be become the first people in decades to legally possess and consume psilocybin mushrooms in Canada after a landmark decision.
The Current Status of Psychedelics in Psychiatry
Dr David Nutt and Dr Robin Carhart-Harris, American Medical Association, 29 July, 2020
The Current Status of Psychedelics in Psychiatry
Psilocybin Therapy for Addiction
60 Minutes USA, 21 July, 2020
Anderson Cooper sits down with Jon Kostakopoulos to discuss his experience as a clinical participant in an NYU psilocybin study treating alcohol use disorder.
Psilocybin & OCD: Can psychedelics treat obsessive compulsive disorder?
New Atlas, 23 July, 2020
A new review from neuroethicist Eddie Jacobs, and published in the Journal of Psychedelic Studies, is suggesting psilocybin may have great potential as a treatment for obsessive-compulsive disorder (OCD).
Lucy in the sky with diamonds
https://www.vogue.pt/english-version-lucy-sky-diamonds, 20 July, 2020
LSD, psilocybin, ecstasy, ayahuasca. From happy trips of the past to mental health of the present, could psychedelics be the future of therapy?
Magic mushrooms could help ex-soldiers to overcome trauma
The Guardian, 04 July, 2020
As more troops self-medicate with psychedelic drugs to help with PTSD, a group of experts lobby for proper clinical trials.
We can no longer ignore the potential of psychedelic drugs to treat depression
https://www.theguardian.com/commentisfree/2020/jun/08/psychedelic-drugs-treat-depression, 08 June, 2020
Imperial College, UK have been comparing psilocybin to conventional antidepressants – and the results are likely to be game-changing
Dr Robin Carhart-Harris is a member of the Mind Medicine Australia advisory panel.
COVID-19 impact likely to lead to increased rates of suicide and mental health
Dr Tony Bartone, Professor Ian Hickie AM, Professor Patrick McGorry AO, AMA Joint Statement, 02 June, 2020
Australia will likely see increases in youth suicide and a surge in demand for specialist mental health services as the full and lasting impact of the COVID-19 pandemic is experienced across the community.
Psychedelics v. Cannabis: In Search of a Better Business Plan
David H., The Cannabis Investor, May 27, 2020, 27 May, 2020
Organizations forming today will build the infrastructure which, three to five years from now, will be delivering psychedelic medicines to the world.
Interim Analysis Shows At Least 90% Chance of Statistically Significant Difference in PTSD Symptoms after MDMA-assisted Psychotherapy
Brad Burge, Multidisciplinary Association for Psychedelic Studies (MAPS), 13 May, 2020
Results are the strongest confirmation that an interim analysis can provide
Psychedelic Pioneer Rick Doblin On FDA Trials Of MDMA: Most Important Reality Check Of MAPS’ 34-Year History
David E. Carpenter, Forbes, 12 May, 2020
Revolutionary drug trial could see ecstasy used as prescription medicine for those living with PTSD and mental illness
Sarah Abo, 60 Minutes Australia, 10 May, 2020
Psychedelic Drugs Can Improve Quality Of Life - And Death - For Older Adults
Abbie Rosner, Forbes, 06 May, 2020
Are Psychedelics Our Most Promising New Treatments for Depression, Anxiety, and Addiction?
Paul Tullis, Town&Country, 13 April, 2020
German Government Funds Psilocybin Study for Depression
Mind and Brain Institute, 24 April, 2020
Coronavirus mental health fallout: Rapid response like psychedelic therapy need of the hour?
Vinay B.S., International Business Times, 13 April, 2020
Can psychedelic therapy reduce the mental health impacts of the coronavirus pandemic?
Morgan Campbell, The Sacramento Bee, 02 April, 2020
This New York City Pharma Startup Wants To Turn LSD Into An FDA-Approved Medicine For Anxiety Disorder
Will Yakowicz, Forbes, 01 April, 2020
Eleusis Announces Published Preclinical Research Revealing Long Lasting Antidepressant-Like Effects of Psychedelics When Compared to Ketamine in Animals
Carol Guaccero, Business Wire, 05 March, 2020
Business gets ready to trip: How psychedelic drugs may revolutionize mental health care
Jeffrey M. O'Brien, Fortune, 19 February, 2020
Microdosed LSD: Finally A Breakthrough For Alzheimer’s Disease?
Abbie Rosner, Forbes, 21 February, 2020
Psychedelics for systems change: could drugs help us save the planet?
Jules Peck, openDemocracy, 15 February, 2020
Move over, pot: Psychedelic companies are about to go public
Kristine Owram, Bloomberg News, 11 February, 2020
Study: Psilocybin From Magic Mushrooms Plus Therapy Delivers Benefits Nearly Five Years Later
David DiSalvo, Forbes, 31 January, 2020
Antianxiety And Antidepressant Effects From A Single Dose Of Psychedelic Drug Persist Years Later In Cancer Patients
Shira Polan, Science Mag, 28 January, 2020
Psychedelics: Can getting high improve your mental health?
Sandee LaMotte, CNN, 20 January, 2020
MDMA inches away from becoming FDA-approved Pharmaceutical
The Waking Times, 20 January, 2020
MDMA treatment for alcoholism could reduce relapse, study suggests
The Guardian, 19 August, 2019
Psychedelics Create New Communication Pathways In The Brain ( Homological Scaffolds )
Beckley Foundation, 17 November, 2017
Watch our brains become more connected on psilocybin, and learn how psychedelics can help treat conditions such as depression, addiction, and PTSD.
Transforming psychedelics into mainstream medicines
Shlomi Raz, Stat News, 07 January, 2019
The future of psychedelic science: What the next decade holds
Rich Haridy, New Atlas, 26 December, 2019
A New Way To Quit? Psychedelic Therapy Offers Promise For Smoking Cessation
Stephanie O'Neill, NPR, 22 December, 2019
MDMA-assisted couples therapy: How a psychedelic is enhancing intimacy and healing PTSD
Anne Wagner, The Conversation, 20 December, 2019
MMA Advisory Panel members Dr Robin Carhart-Harris and Dr Rosalind Watts have joined the Advisory Board for Synthesis Retreat in the Netherlands
Jessica McCulloch, 09 December, 2019
Microdosing LSD for Alzheimer’s proves safe in early human trial
Rich Haridy, New Atlas, 18 December, 2019
Psilocybin for major depression granted Breakthrough Therapy by FDA
Rich Haridy, The Atlas, 24 November, 2019
The Return Trip: Psychedelics may come back from the abyss of illegality
Peter Stilla, Valley Advocate, 20 November, 2019
Psilocybin-assisted therapy for depression: How do we advance the field?
David Castle, Australian & New Zealand Journal of Psychiatry, 19 November, 2019
Magic mushroom compound psilocybin shows promise for treatment of anxiety and depression
Robyn Williams, The Science Show, ABC Radio National, 11 November, 2019
Health Report with Norman Swan
Dr Norman Swan, On Breakfast Program with Hamish Macdonald, ABC Radio National, 11 November, 2019
Research into psychedelic drugs like LSD is growing, encouraged by positive early trials. Scientists think these drugs could treat things like post-traumatic stress disorder and depression.
What Happened When I Sought Alternative Mental Health Treatment Abroad
Lizbeth Finn-Arnold, The Mighty, 11 November, 2019
Why Psychedelics Could be the Future of Anorexia Treatment
Tessa Love, Elemental Medium, 06 November, 2019
Clinical Trials Show Antidepressants “Not Beneficial in the Long Term”
MAD in America, 07 October, 2019
Field Trip Ventures Inc. Partners with the University of the West Indies to Create the World's First Legal Research and Cultivation Facility for Psilocybin
PR Newswire, 19 September, 2019
Magic Mushrooms As Medicine? Johns Hopkins Scientists Launch Center For Psychedelic Research. Say Psychedelics Could Treat Alzheimer’s, Depression And Addiction.
Forbes Magazine, 12 September, 2019
Usona Institute Clinical Trial of Psilocybin for Major Depressive Disorder Launching This Fall
Business Wire, 09 September, 2020
Tim Ferris, the man who put his money behind psychedelic medicine
Benedict Carey, The New York Times, 09 September, 2019
John Hopkins opens new center for Psychedelic Research
Benedict Carey, The New York Times, 05 September, 2019
Magic Mushroom Psilocybin being Researched as Aid for Alzeimer's & Depression
Andrew Whalen, Newsweek, 04 September, 2019
World-first trial investigating psilocybin psychotherapy for anorexia commencing in US
Rich Haridy, New Atlas, 27 August, 2019